Could a malaria drug and a transplant drug keep breast cancer from returning?
NCT ID NCT03032406
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This pilot trial investigates whether hydroxychloroquine (a malaria drug) and everolimus (an immune-suppressing drug), taken alone or together, can help prevent breast cancer from returning in high-risk patients. The study enrolls people who have completed primary treatment for stage IIB breast cancer but still have cancer cells in their bone marrow. The main goal is to see if the treatment is safe and tolerable enough to continue testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxychloroquine and everolimus
What this could lead to
If successful, this approach could point toward a new strategy to prevent breast cancer from coming back in patients who have completed initial treatment.
What could go wrong
This is a small, early-phase pilot trial focused on feasibility and safety, not effectiveness. The drugs may cause side effects, and the COVID-19 pandemic disrupted enrollment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IIB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States